Evidence map›Paper›PMID 30789361›Full record

ArticleAnti-cancer drugs2019

Evodiamine inhibits migration and invasion by Sirt1-mediated post-translational modulations in colorectal cancer.

Peng Zhou, Xiao-Peng Li, Rong Jiang, Yi Chen, Xiao-Ting Lv, Xing-Xian Guo, Kuan Tian, De-Zhi Yuan, Yan-Wei Lv, Jian-Hua Ran and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Anti-cancer drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. The role of SIRT1 in the development of gastrointestinal tumors.Frontiers in cell and developmental biology · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Research progress on evodiamine, a bioactive alkaloid ofExperimental and therapeutic medicine · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Peng ZhouLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Xiao-Peng LiLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Rong JiangLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Yi ChenLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Xiao-Ting LvLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Xing-Xian GuoLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Kuan TianLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
De-Zhi YuanLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Yan-Wei LvLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Jian-Hua RanLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Jing LiLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Di-Long ChenLaboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology.
Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most difficult cancers to cure. An important prognostic factor is metastasis, which precludes curative surgical resection. Recent evidences show that Evodiamine (EVO) exerts an inhibitory effect on cancer cell apoptosis, migration, and invasion. In this study, we investigated the effects of EVO on the metastasis of CRC cells in vitro and in vivo. In vitro, wound-healing and transwell assay showed that migration and invasion of HT-29 and HCT-116 CRC cells were inhibited significantly by EVO. Western blot and RT-PCR showed that EVO reduced the expression of matrix metalloproteinase-9 in a dose-dependent manner. In EVO-induced cells, the intracellular NAD+/NADH ratio was increased, the level of Sirt1 was increased, and acetyl-NF-κB P65 was decreased. This process was inhibited by nicotinamide, an inhibitor of Sirt1. In vivo, EVO reduced tumor metastasis markedly. These findings provide evidences that EVO suppresses the migration and invasion of CRC cells by inhibiting the acetyl-NF-κB p65 by Sirt1, resulting in suppression of metalloproteinase-9 expression in vitro and in vivo.

Indexed as

Cell MovementAnimalsApoptosisBiomarkers, TumorCell ProliferationColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansLung NeoplasmsMatrix Metalloproteinase 9MiceMice, Inbred BALB CMice, NudeNeoplasm InvasivenessNF-kappa BBiomarkers, TumorevodiamineMatrix Metalloproteinase 9NF-kappa BQuinazolinesSIRT1 protein, humanSirtuin 1

Identifiers

PMID30789361
PMCPMC6530977
OpenAlexW2915095243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.